Affiliation:
1. Department of Obstetrics & Gynecology
2. Division of Gynecologic Oncology, Northwestern University Feinberg School of Medicine
3. Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois
Abstract
Racial inequities are well-documented across the gynecologic oncology care continuum, including the representation of racial and ethnic minoritized groups (REMGs) in gynecologic oncology clinical trials. We specifically reviewed the scope of REMG disparities, contributing factors, and strategies to improve inclusion. We found systematic and progressively worsening under-enrollment of REMGs, particularly of Black and Latinx populations. In addition, race/ethnicity data reporting is poor, yet a prerequisite for accountability to recruitment goals. Trial participation barriers are multifactorial, and successful remediation likely requires multi-level strategies. More rigorous, transparent data on trial participants and effectiveness studies on REMG recruitment strategies are needed to improve enrollment.
Publisher
Ovid Technologies (Wolters Kluwer Health)
Subject
Obstetrics and Gynecology
Reference81 articles.
1. Cancer statistics for African Americans, 2019;DeSantis;CA Cancer J Clin,2019
2. Towards the elimination of health care disparities in gynecologic oncology: Call to action;Del Carmen;Gynecol Oncol,2018
3. Investigating Black-White disparities in gynecologic oncology: Theories, conceptual models, and applications;Doll;Gynecol Oncol,2018
4. Not immune to inequity: minority under-representation in immunotherapy trials for breast and gynecologic cancers;Grette;Int J Gynecol Cancer,2021
5. Participation in cancer clinical trials: race-, sex-, and age-based disparities;Murthy;JAMA,2004
Cited by
9 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献